BACKGROUND: Programmed death 1 (PD-1) programmed death-ligand 1 (PD-L1) inhibitors show significant clinical activity in non-small cell lung carcinoma (NSCLC). However, they are often associated with potentially fatal immune-mediated pneumonitis. Preliminary reports of trials suggest a difference in the rate of pneumonitis with PD-1 and PD-L1 inhibitors. We sought to determine the overall incidence of pneumonitis and differences according to type of inhibitors and prior chemotherapy use.
Programmed death 1 (PD-1) and programmed deathligand 1 (PD-L1) inhibitors have shown clinical activity and marked efficacy in the treatment of non-small cell lung cancer (NSCLC). Nivolumab and pembrolizumab, both PD-1 inhibitors, and atezolizumab, a PD-L1 inhibitor, are Food and Drug Administration (FDA)-approved treatments for patients with advanced NSCLC. In addition, pembrolizumab was recently FDA approved for treatment of patients with NSCLC in the frontline setting when the tumor PD-L1 expression is > 50%. Avelumab and durvalumab, two other PD-L1 inhibitors, are also being evaluated in multiple clinical trials in patients with advanced NSCLC. Monoclonal antibodies against PD-1 and PD-L1 inhibit immune checkpoint receptors and can disrupt normal mechanisms of immune tolerance, resulting in increased immune activation in normal tissue. 1, 2 This results in abundant unregulated activation of T cells causing significant toxicity and is the basis for immune-related adverse events with these agents. 3 Pneumonitis is an important autoimmune toxicity associated with the use of anti-PD-1/PD-L1 antibodies, resulting in significant morbidity and mortality, often resulting in discontinuation of therapy. 4, 5 Previous studies have demonstrated a rate of pneumonitis of approximately 4% in patients with NSCLC, higher than in patients with other types of tumors. 6 However, there has been no report of a systematic review or meta-analysis comparing the incidence of pneumonitis between PD-1 inhibitors and PD-L1 inhibitors. Given the recent FDA approval of both PD-1 and PD-L1 inhibitors for previously treated NSCLC patients, such an analysis will add insights into this potentially lethal adverse event.
With the recent approval of pembrolizumab in the frontline setting in selected patients, and numerous recent trials with these agents in treatment naive patients, a secondary objective of our study was to compare the rates of pneumonitis in patients treated with immune-checkpoint inhibitors in the frontline setting compared with patients with previous lines of treatment.
Methods
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement to report this systematic review and meta-analysis. 
Study Selection and Data Extraction
The following predetermined inclusion criteria were used: (1) singlearm or randomized trials evaluating PD-1 and PD-L1 inhibitors in NSCLC; (2) data available on rates of pneumonitis assessed by the Common Terminology Criteria for Adverse Events Version 4.0; and (3) in studies that used PD-1 and PD-L1 inhibitors in combination with other agents, only the arms of the study with a single agent were eligible. Abstracts and conference proceedings from the previous 5 years were included if all relevant data were provided. Unpublished trials and letters to the editor were not eligible. Two investigators (M. K. and S. R.) independently reviewed the list of retrieved articles to choose potentially relevant articles, and disagreements about particular studies were discussed and resolved with consensus. Two reviewers (M. K. and S. R.) independently extracted data from studies using standardized data extraction sheets, and all discrepancies were resolved in consensus. The following information was extracted: name of study, first author and year of publication, study design and blinding, mean age, sex distribution, follow-up time, line of therapy, study phase, study drug, rates of any grade, and grade $ 3 pneumonitis. The primary outcome of interest was the rate of pneumonitis; we also evaluated grade $ 3 pneumonitis.
Risk of Bias Assessment
We used the Cochrane risk of bias assessment to explore sources of bias in included randomized trials. 8 This scale evaluates the following criteria: (1) randomized sequence generation, (2) allocation concealment, (3) blinding of participants, personnel, and outcome assessors, (4) incomplete outcome data, (5) selective outcome reporting, and (6) other sources of bias. Risk of bias was labeled as high, low, or unclear. If any item of randomization or blinding was judged as high risk, then the trial had high risk of bias. Single-arm trials have a high risk of bias by their nature; therefore, they were not further assessed for bias.
Data Synthesis and Analysis
Some degree of heterogeneity was expected, and analyses were performed using DerSimonian-Laird random effects models. We used the inverse variance method to calculate pooled incidence of pneumonitis and their 95% CIs. Statistical heterogeneity was evaluated with the Cochran c 2 test and the I 2 statistics. A P value of < .10 for c 2 was defined as indicating the presence of heterogeneity. I 2 values of 30% to 60% represented a moderate level of heterogeneity. The primary comparisons were between PD-1 and PD-L1 inhibitors and between treatment naive and previously treated patients; these incidence differences were tested with the z test. We used the metafor package of R 3.3.2 (The R Foundation) for our statistical analyses.
Results

Eligible Studies
Our search retrieved 3,504 publications. After excluding duplicates and screening titles of the studies, 108 articles were selected on the basis of relevance to the study topic. After abstract and full article review, 19 distinct trials were included. All studies were published in the last 5 years. We found 12 trials with PD-1 inhibitors (nivolumab: n ¼ 9, pembrolizumab: n ¼ 3) and 7 trials with PD-L1 inhibitors (atezolizumab: n ¼ 5, durvalumab: n ¼ 1, avelumab: n ¼ 1). The reasons for exclusion are listed in Figure 1 .
Characteristics of Studies Included in the Meta-Analysis Table 1 4,5,9-26 summarizes the main characteristics of the included studies and details of the incidence of pneumonitis for all grade and for grade $ 3 pneumonitis in patients treated with PD-1 and PD-L1 inhibitors. There were six phase I trials, six phase II trials, and seven phase III trials; 13 were single-arm trials, and 6 were randomized controlled trials. Mean age of patients was 64 years, and 64% of patients were men. Study follow-up ranged from 10 to 168 weeks. The number of patients studied across trials ranged between 35 and 807 patients.
Risk of Bias Assessment
Most of the studies had high risk of selection bias, performance bias, and detection bias because most were open-label, single-arm trials. All or most of the included randomized trials had a low risk of reporting bias, attrition bias, and other bias (Fig 2) . chestjournal.org (Fig 3) . Also, we found a higher incidence of grade $ 3 pneumonitis with PD-1 inhibitors in comparison with PD-L1 inhibitors (1.1%; 95% CI, 0.6%-1.7% vs 0.4%; 95% CI, 0%-0.8%, respectively; P ¼ .02) (Fig 4) .
There was higher heterogeneity in the rate of pneumonitis in trials with PD-1 inhibitors for all grade and for grade $ 3 pneumonitis (72.30% and 55%, respectively) compared with trials with PD-L1 inhibitors (1.97% and 30%, respectively). Because of higher heterogeneity in the incidence of pneumonitis in the PD-1 inhibitors group, we further performed a subgroup analysis among all trials with nivolumab and pembrolizumab, and it did not yield any significant differences in rates of pneumonitis between these two PD-1 inhibitors.
Incidence of Pneumonitis Between Treatment Naive vs Previously Treated Patients Table 2 represents the incidence of all grade and grade 3 or 4 pneumonitis in treatment naive and previously treated patients. In patients receiving either PD-1 or PD-L1 inhibitors, we found a significantly higher rate of pneumonitis in treatment naive patients than in previously treated patients (4.3%; 95% CI, 2.4%-6.3% vs 2.8%; 95% CI, 1.7%-4%, respectively; P ¼ .03) (Fig 5) . There were no significant differences in the incidences of grade $ 3 pneumonitis in treatment naive and previously treated patients (0.5%; 95% CI, 0%-1.1% vs 1%; 95% CI, 0.5%-1.5%, respectively; P ¼ .10) See Table 1 legend for expansion of abbreviations.
( Fig 6) . Finally, there were no significant differences in the incidence of both any grades of pneumonitis and grade $ 3 pneumonitis between treatment naive and previously treated patients when analysis was stratified by PD-1 inhibitors trials and PD-L1 inhibitors trials.
Discussion
In the present meta-analysis of all published clinical trials of PD-1 and PD-L1 inhibitor therapy for patients with NSCLC, the overall incidence of all grade pneumonitis in PD-1 inhibitor group was 3.6% and in the PD-L1 inhibitor group was 1.3%, a difference that was significant. Grade $ 3 pneumonitis incidence was significantly higher for PD-1 inhibitors as well.
Use of PD-1 and PD-L1 inhibitors in the frontline setting was associated with significantly higher incidence of all grade pneumonitis compared with previously treated patients; grade $ 3 pneumonitis incidence was nonsignificantly lower in treatment naïve patients in comparison with previously treated patients.
To our knowledge, this is the first meta-analysis report that focuses on differences in the rates of pneumonitis in patients treated with PD-1 inhibitors compared with PD-L1 inhibitors. In addition, we have also reported the differences in rates of pneumonitis when PD-1 and PD-L1 inhibitors are used in treatment naive patients compared with their use in patients with previously treated advanced NSCLC. Pneumonitis, especially high-grade pneumonitis, is associated with increased mortality in patients with NSCLC treated with PD-1/PD-L1 inhibitors. In the setting of underlying pulmonary pathologies, such as COPD and interstitial lung diseases, in patients with lung cancer often as a result of smoking exposure, early diagnosis of pneumonitis is challenging, and failure to recognize the symptoms and signs of pneumonitis could lead to poor outcomes. Hence recognizing the differences in the incidence of pneumonitis across PD-1 and PD-L1 inhibitors will help patients and clinicians make informed treatment decisions. This is especially relevant because both PD-1 and PD-L1 inhibitors are approved for use in previously treated NSCLC, with no clear differentiation between agents based on efficacy.
There were seven deaths attributed to pneumonitis, all in patients who had been treated with PD-1 inhibitors. Across all the trials, no clear relationship between the occurrence of pneumonitis and treatment duration or dose level was noted. 18, 23, 25 Baseline characteristics of only seven patients who developed pneumonitis were described across three clinical trials. 4, 23, 24 Six out of these seven patients were former smokers, and three out of these seven patients were treated with radiation therapy prior to PD-1/ PD-L1 inhibitor therapy. Large clinical trials are needed to establish the risk factors associated with development of pneumonitis with PD-1/PD-L1 inhibitors, including smoking history and prior radiation therapy.
The role of the different PD-1 ligands in pneumonitis is not yet clearly understood. A valid hypothesis explaining the lower incidence of pneumonitis in PD-L1 inhibitors could be the sparing of PD-1/programmed death-ligand 2 (PD-L2) interaction with PD-L1 inhibitors, which might be an important player in mediating immune tolerance in the lungs. Experiments in murine models suggest that PD-1 blockade may shift the balance in PD-L2 interaction with its other binding partners, increasing PD-L2 availability for binding to repulsive guidance molecule b, which can lead to pneumonitis. 27 This interaction might be particularly important in patients with smoking history because cigarette smoking is associated with tumorigenesis by natural killer cell and T cell-mediated inflammatory response. 28 pneumonitis as compared with melanoma and similarly patients with squamous cell carcinoma have been observed to have higher pneumonitis incidence as compared with nonsquamous histology, further supporting this hypothesis. [4] [5] [6] We observed a significantly higher rate of all grade pneumonitis in treatment naive patients. This is an important area for further investigation in the light of recent FDA approval of pembrolizumab in the frontline setting in selected patients. Regardless, such observations highlight that the chances of developing lethal immune-related adverse events, such as pneumonitis, are dependent on many factors, including clinical course and treatment outcomes, and large clinical trials are needed to establish conclusive evidence.
Our current meta-analysis reporting difference in the rate of pneumonitis between PD-1 and PD-L1 inhibitors is plagued by certain limitations. Many studies included in the meta-analysis were open label, introducing high chances of bias in collection and reporting of pneumonitis. However, such a bias should not be significant because evaluation for pneumonitis was done with objective radiologic parameters unlike subjective adverse events. Only side effects reported as pneumonitis were included in this meta-analysis, and other side effects listed as interstitial lung disease or pneumonia were excluded to include only the confirmed pneumonitis cases.
Lack of randomized clinical trials directly comparing PD-1 inhibitors with PD-L1 inhibitors prevents us from making a firm conclusion. The current study however is the first most comprehensive effort at comparing the rates of pneumonitis between PD-1 and PD-L1 inhibitors. Various trials used different dosing and treatment schedules; however, the rates of pneumonitis were included for the entire cohort because data for incidence of pneumonitis for each treatment dose and frequency was not available. As more and more patients are being treated with PD-1/ PD-L1 inhibitors each day, future efforts directed at identifying patients who are more likely to develop pneumonitis, including patients with underlying lung 
Conclusions
This analysis suggests that PD-1 inhibitors are associated with a significantly higher incidence of pneumonitis than PD-L1 inhibitors. This finding may impact clinical selection of these agents given their overlapping indications in NSCLC. Further understanding of the role of PD-1 and its ligands in generating pneumonitis can yield important clues toward development of safer immune checkpoint therapies. In addition, we observed a significantly higher rate of pneumonitis in treatment naive patients treated with a PD-1/PD-L1 inhibitor, which merits further investigation. A B Figure 6 -Incidence of grade $ 3 pneumonitis in studies evaluating treatment naive patients (A) and previously treated patients (B). See Figure 4 legend for expansion of abbreviation.
